NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Alphabet-C
GOOG
US Stock MarketDetailed Quotes
AKRO Akero Therapeutics
- 29.340
- +0.940+3.31%
Close Dec 20 16:00 ET
- 29.340
- 0.0000.00%
Post 16:11 ET
2.05BMarket Cap-7.76P/E (TTM)
29.770High28.090Low1.56MVolume28.090Open28.400Pre Close45.63MTurnover2.84%Turnover RatioLossP/E (Static)69.80MShares37.00052wk High2.77P/B1.61BFloat Cap15.32052wk Low--Dividend TTM54.91MShs Float58.380Historical High--Div YieldTTM5.92%Amplitude7.520Historical Low29.249Avg Price1Lot Size
About Akero Therapeutics Company
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Company Profile
SymbolAKRO
Company NameAkero Therapeutics
Listing DateJun 20, 2019
Issue Price16.00
Founded2017
CEODr. Andrew Cheng, M.D.,PhD
MarketNASDAQ
Employees56
Fiscal Year Ends12-31
Address601 Gateway Boulevard,Suite 350
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080-7006
Phone1-650-487-6488
Websitehttp://www.akerotx.com
Company Executives
- Name
- Position
- Salary
- Dr. Andrew Cheng, M.D.,PhD
- President, Chief Executive Officer and Director
- 8.83M
- Dr. Jonathan Young, J.D.
- Executive Vice President, Chief Operating Officer and Secretary
- 3.44M
- Catriona Yale
- Chief Development Officer
- 3.45M
- William R. White, J.D.
- Principal Accounting Officer, Executive Vice President, Treasurer, Chief Financial Officer and Head, Corporate Development
- 4.29M
- Dr. Timothy Rolph, D.Phil.
- Chief Scientific Officer
- 3.49M
- Patrick Lamy
- Senior Vice President, Commercial Strategy
- --
- Mark T. Iwicki
- Chairman of the Board
- 606.06K
- Jane Pritchett Henderson
- Independent Director
- 586.06K
- Dr. Judy Chou, PhD
- Independent Director
- 571.06K
- Dr. Seth L. Harrison, M.D.
- Independent Director
- 568.56K
- Dr. Graham Waley, M.D.,PhD
- Independent Director
- 578.56K
- Dr. Yuan Xu, PhD
- Independent Director
- 573.56K
- Tomas J. Heyman
- Independent Director
- 581.06K
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.